Table 2 Response to induction therapy... | American Society of Hematology

Table 2

Response to induction therapy and outcome in 1,700 younger adult patients with AML according to DNMT3A mutation status

Response to double induction	DNMT3A^wt (n = 1333)		All DNMT3A^mut (n = 367)		P*	R882-DNMT3A^mut (n = 239)		non-R882 DNMT3A^mut (n = 128)		P†
Response to double induction	No.	%	No.	%	P*	No.	%	No.	%	P†
Entire cohort
CR	952	71.4	289	78.7	.005	194	81.2	95	74.2	.14
RD	281	21	58	15.8	.027	32	13.4	26	20.3	.098
ED/HD	100	7.5	20	5.4	.21	13	5.4	7	5.5	.99
CN-AML
CR	408	77.9	217	81.6	.27	151	80.7	66	83.5	.73
RD	87	16.6	35	13.2	.21	27	14.4	8	10.1	.43
ED/HD	29	5.5	14	5.2	.99	9	4.9	5	6.3	.56
CN-AML, ELN favorable
CR	147	90.8	98	87.5	.43	68	87.2	30	88.2	.99
RD	8	4.9	8	7.2	.45	6	7.7	2	5.9	.99
ED/HD	7	4.3	6	5.3	.78	4	5.1	2	5.9	.99
CN-AML, ELN unfavorable
CR	209	69.4	102	76.1	.17	76	76.8	26	74.3	.82
RD	70	23.3	24	17.9	.26	18	18.2	6	17.1	.99
ED/HD	22	7.3	8	6	.99	5	5.1	3	8.6	.43

Response to double induction	DNMT3A^wt (n = 1333)		All DNMT3A^mut (n = 367)		P*	R882-DNMT3A^mut (n = 239)		non-R882 DNMT3A^mut (n = 128)		P†
Response to double induction	No.	%	No.	%	P*	No.	%	No.	%	P†
Entire cohort
CR	952	71.4	289	78.7	.005	194	81.2	95	74.2	.14
RD	281	21	58	15.8	.027	32	13.4	26	20.3	.098
ED/HD	100	7.5	20	5.4	.21	13	5.4	7	5.5	.99
CN-AML
CR	408	77.9	217	81.6	.27	151	80.7	66	83.5	.73
RD	87	16.6	35	13.2	.21	27	14.4	8	10.1	.43
ED/HD	29	5.5	14	5.2	.99	9	4.9	5	6.3	.56
CN-AML, ELN favorable
CR	147	90.8	98	87.5	.43	68	87.2	30	88.2	.99
RD	8	4.9	8	7.2	.45	6	7.7	2	5.9	.99
ED/HD	7	4.3	6	5.3	.78	4	5.1	2	5.9	.99
CN-AML, ELN unfavorable
CR	209	69.4	102	76.1	.17	76	76.8	26	74.3	.82
RD	70	23.3	24	17.9	.26	18	18.2	6	17.1	.99
ED/HD	22	7.3	8	6	.99	5	5.1	3	8.6	.43

CR, complete remission; RD, refractory disease; ED, early death; HD, hypoplastic death.

Comparison of DNMT3A^wt vs DNMT3A^mut.

Comparison of R882-DNMT3A^mut vs non-R882-DNMT3A^mut.